Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 2/20 | 0.38 |
| ▸ | AURKA | O14965 | 15/20 | 0.36 |
| ▸ | RPS6KB1 | P23443 | 15/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.31 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19640483 | 0.91 | NSD2 (0.40) | RORCAURKARPS6KB1AURKB | |
| SCHEMBL19640764 | 0.89 | AURKA (0.42) | RORCAURKARPS6KB1AURKB | |
| SCHEMBL19640477 | 0.87 | RPS6KB1 (0.48) | RORCAURKARPS6KB1AURKB | |
| SCHEMBL19640482 | 0.87 | RORC (0.39) | RORCAURKARPS6KB1AURKBHTR2A | |
| SCHEMBL19640448 | 0.86 | RORC (0.38) | RORCAURKARPS6KB1AURKBHTR2A | |
| SCHEMBL19640735 | 0.86 | AURKA (0.38) | RORCAURKARPS6KB1AURKB | |
| SCHEMBL19650845 | 0.85 | RPS6KB1 (0.42) | RORCAURKARPS6KB1AURKB | |
| SCHEMBL19640438 | 0.85 | RPS6KB1 (0.47) | RORCAURKARPS6KB1AURKB | |
| SCHEMBL19640527 | 0.84 | VNN1 (0.39) | RORCAURKARPS6KB1AURKB | |
| SCHEMBL19640661 | 0.84 | RORC (0.42) | RORCAURKARPS6KB1AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170342074-A1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | NUEVOLUTION A/S (DK) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342074-A1 | OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES | PPARD, PPARG, RORC | RORC 3/4885AURKA 1448/4885RPS6KB1 1118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.